H.C. Wainwright Downgrades Melinta Therapeutics Inc (MLNT) to Hold
In a report released today, Ed Arce from H.C. Wainwright downgraded Melinta Therapeutics Inc (MLNT) to Hold. The company’s shares closed on Friday at $2.85, close to its 52-week low of $1.62.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 6.5% and a 34.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Conatus Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Melinta Therapeutics Inc with a $15 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.50 and a one-year low of $1.62. Currently, Melinta Therapeutics Inc has an average volume of 2.66M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Melinta Therapeutics, Inc. operates as a commercial-stage pharmaceutical company which engages in developing and commercializing anti-infective s for the hospital and selected non-hospital or communities. It markets antibiotics including Baxdela, Vabomere, Orbactiv, and Minocin for injections.